Literature DB >> 6289060

Epstein-Barr virus induced proteins V: comparison of EBV-specific polypeptides from different virus strains.

B Georg-Fries, N Mueller-Lantzsch.   

Abstract

EBV-associated polypeptides induced in different Epstein-Barr Virus (EBV)-producing cell lines by the tumor promotor TPA, and from purified EBV particles derived from the same lines were radioactivity labeled and analyzed by immunoprecipitation with human VCA+MA+ sera. In virus-producing cells no significant differences in the molecular weight of 35S-methionine-labeled EBV-associated polypeptide patterns could be observed. The analysis 125I-labeled polypeptides from purified virus particles of four different strains revealed that, in addition to common polypeptides, individual EBV strains contain strain-specific high molecular weight glycopolypeptides. These polypeptides, constituting part of the membrane antigen complex, are present in varying amounts. While P3HR-1 virus particles contain a major component of 250 000 and small amounts of 340 000 molecular weight polypeptides, Q IMR-WIL virus particles have more 340 00 than 240 000 molecular weight polypeptides. Furthermore, in B95-8 particles and in particles from an EBV strain isolated from an African green monkey (AGM-EBV) respectively, large amounts of 360 000 and 250 000 polypeptides could be observed. Since these glycopolypeptides carry strain-, subgroup- and group-specific antigenic determinants, also found in virus strains produced in human and marmoset cells, it should be further investigated whether these differences in molecular weight are virus-strain- or cell-specific.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289060     DOI: 10.1007/bf02122703

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  29 in total

1.  Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus.

Authors:  M Dolyniuk; E Wolff; E Kieff
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

2.  Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus.

Authors:  M Dolyniuk; R Pritchett; E Kieff
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

3.  DNA of Epstein-Barr virus. I. Comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness.

Authors:  R F Pritchett; S D Hayward; E D Kieff
Journal:  J Virol       Date:  1975-03       Impact factor: 5.103

4.  Tumor initiators and promoters in the induction of Epstein-Barr virus.

Authors:  H zur Hausen; G W Bornkamm; R Schmidt; E Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

5.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

6.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.

Authors:  B C Strnad; T Schuster; R Klein; R F Hopkins; T Witmer; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

9.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

10.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.